287 related articles for article (PubMed ID: 20308379)
1. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
Page MG; Dantier C; Desarbre E
Antimicrob Agents Chemother; 2010 Jun; 54(6):2291-302. PubMed ID: 20308379
[TBL] [Abstract][Full Text] [Related]
2. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.
Mushtaq S; Warner M; Livermore D
J Antimicrob Chemother; 2010 Feb; 65(2):266-70. PubMed ID: 19996139
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Hofer B; Dantier C; Gebhardt K; Desarbre E; Schmitt-Hoffmann A; Page MG
J Antimicrob Chemother; 2013 May; 68(5):1120-9. PubMed ID: 23344577
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
Hornsey M; Phee L; Stubbings W; Wareham DW
Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.
van Delden C; Page MG; Köhler T
Antimicrob Agents Chemother; 2013 May; 57(5):2095-102. PubMed ID: 23422914
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
[TBL] [Abstract][Full Text] [Related]
8. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii.
Russo TA; Page MG; Beanan JM; Olson R; Hujer AM; Hujer KM; Jacobs M; Bajaksouzian S; Endimiani A; Bonomo RA
J Antimicrob Chemother; 2011 Apr; 66(4):867-73. PubMed ID: 21393224
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
11. Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Noel AR; Attwood M; Bowker KE; MacGowan AP; Albur M
J Antimicrob Chemother; 2022 Apr; 77(5):1306-1312. PubMed ID: 35137096
[TBL] [Abstract][Full Text] [Related]
12. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii.
Higgins PG; Stefanik D; Page MG; Hackel M; Seifert H
J Antimicrob Chemother; 2012 May; 67(5):1167-9. PubMed ID: 22294643
[TBL] [Abstract][Full Text] [Related]
14. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
[TBL] [Abstract][Full Text] [Related]
15. Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393).
Krajnc A; Gobec S
Expert Opin Ther Pat; 2023; 33(7-8):471-476. PubMed ID: 37902072
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
17. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
Thabaut A; Meyran M; Huerre M
Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
[TBL] [Abstract][Full Text] [Related]
18. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
19. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
Montaner M; Lopez-Argüello S; Oliver A; Moya B
Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
